OnKure Therapeutics, Inc. OKUR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on assets | -39.4%+27.9pp | -67.2%+17.1pp | -84.3%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 13.8×+3.5× | 10.3×-1.2× | 11.4×+0.3× | 11.1×0.0× | 11.2×+0.4× | |
| Quick ratio | 13.8×+3.5× | 10.3×-1.2× | 11.4×+0.3× | 11.1×0.0× | 11.2×+0.4× | |
| Cash ratio | 13.4×+3.4× | 10×-1.3× | 11.3×+0.3× | 11×0.0× | 11×+0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×— | —— | —— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $13.48+224% | $4.16-15.3% | $4.91-15.2% | $5.79-14.3% | $6.75-77.6% | |
| Valuation | ||||||
| Market capitalization | $184.2M+72.6% | $123.71M+5.6% | $117.16M— | —— | —— | |
| Enterprise value | -$7.49M-127% | $65.21M+37.3% | $47.51M— | —— | —— | |
| Price / book | 1×-0.4× | 2.2×+0.4× | 1.8×— | —— | —— | |
| Free cash flow yield | -27.5%+29.8pp | -41.9%+12.5pp | -54.4%— | —— | —— | |
| Earnings yield | -31.8%+24.5pp | -48.1%+6.1pp | -54.2%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do OnKure Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from OnKure Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.